Background
Application of genetically
modified non-pathogenic bacteria expressing specific anti-tumor proteins
under certain conditions specific to tumors is an effective approach for
selective targeting of tumors. We developed
here, for the first time, a novel
spatiotemporal cancer targeted therapy applying engineered E. coli
bacteria with capability of expressing cardiac peptides under hypoxic
conditions of tumor.